Universe Pharmaceuticals Financials

UPC Stock  USD 3.84  3.75  4,259%   
Based on the key indicators related to Universe Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Universe Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, Universe Pharmaceuticals' Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Retained Earnings is expected to grow to about 13.6 M, whereas Total Assets are forecasted to decline to about 47.2 M. Key indicators impacting Universe Pharmaceuticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.170.16
Notably Up
Slightly volatile
Current Ratio2.222.41
Significantly Down
Slightly volatile
The essential information of the day-to-day investment outlook for Universe Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Universe Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Universe Pharmaceuticals.

Net Income

(5.27 Million)

  
Please note, the presentation of Universe Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Universe Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Universe Pharmaceuticals' management manipulating its earnings.

Universe Pharmaceuticals Stock Summary

Universe Pharmaceuticals competes with Regencell Bioscience, Im Cannabis, Raphael Pharmaceutical, Procaps Group, and Phibro Animal. Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. Universe Pharmaceuticals is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINKYG9442G1047
CUSIPG9442G104 G9442G112 G9442G120
LocationChina
Business Address265, Jingjiu Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.universe-pharmacy.com
Phone86 79 6840 3309
CurrencyUSD - US Dollar

Universe Pharmaceuticals Key Financial Ratios

Universe Pharmaceuticals Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets28.8M70.1M59.5M53.3M61.3M47.2M
Other Current Liab1.3M464.0K5.9M3.3M2.9M3.2M
Net Tangible Assets12.2M20.6M58.8M46.3M53.2M32.4M
Net Debt(7.4M)(3.7M)(1.8M)197.2K226.8K238.1K
Retained Earnings13.7M25.1M16.3M10.2M11.7M13.6M
Accounts Payable2.7M5.3M3.1M4.6M5.3M3.8M
Cash10.1M8.1M5.7M5.3M6.1M7.1M
Other Assets168.1K186.5K14.1M12.9M14.9M15.6M
Net Receivables10.9M15.8M15.2M10.7M12.3M12.2M
Inventory1.9M2.5M2.2M3.3M3.0M2.8M
Other Current Assets443.7K10.4M5.3M4.2M4.9M3.7M
Total Liab8.0M11.2M13.1M13.8M15.8M12.8M
Net Invested Capital23.4M63.3M50.4M45.0M51.8M38.4M
Short Long Term Debt2.6M4.3M3.9M5.5M6.3M3.9M
Total Current Assets23.3M50.5M41.5M36.8M42.3M34.1M
Net Working Capital15.3M39.3M28.4M23.1M26.5M21.3M
Short Term Debt2.6M4.3M3.9M5.5M6.3M3.9M
Intangible Assets174.8K178.5K157.5K148.6K133.7K135.3K

Universe Pharmaceuticals Key Income Statement Accounts

202020212022202320242025 (projected)
Tax Provision2.5M2.4M752.4K2.3M2.1M1.6M
Net Interest Income(123.8K)(101.6K)(162.4K)(156.8K)(141.1K)(148.2K)
Interest Expense123.8K101.6K162.4K156.8K180.3K153.8K
Total Revenue30.7M48.0M40.1M32.3M37.2M39.0M
Gross Profit14.1M25.3M21.9M10.3M11.9M18.0M
Operating Income10.3M13.6M(7.0M)(3.5M)(3.2M)(3.0M)
Ebit10.2M13.7M(7.9M)(3.7M)(3.4M)(3.2M)
Research Development583.1K5.5M7.6M4.9M5.6M3.7M
Ebitda10.6M14.2M(7.3M)(3.2M)(2.9M)(2.7M)
Cost Of Revenue16.6M22.7M18.3M22.0M25.3M21.0M
Income Before Tax10.1M13.7M(8.0M)(3.8M)(3.5M)(3.3M)
Net Income7.6M11.3M(8.7M)(6.2M)(5.5M)(5.3M)
Income Tax Expense2.5M2.4M752.4K2.3M2.1M1.6M

Universe Pharmaceuticals Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory888.6K(451.6K)16.6K(1.2M)(1.1M)(1.0M)
Investments(51.8K)(13.5M)(3.9M)(44.2K)(39.8K)(41.7K)
Change In Cash6.9M(2.0M)(2.4M)(426.2K)(383.6K)(402.8K)
Net Borrowings1.1K911.2K624.4K3.3M3.8M4.0M
Free Cash Flow6.1M(15.6M)(1.4M)1.1M968.3K1.0M
Depreciation410.1K446.9K533.9K508.8K585.1K508.0K
Other Non Cash Items22.7K(468.2K)906.6K(526.9K)(474.2K)(450.5K)
Capital Expenditures51.8K13.5M93.7K44.2K50.8K48.3K
Net Income7.6M11.3M(8.7M)(6.2M)(5.5M)(5.3M)
End Period Cash Flow10.1M8.1M5.7M5.3M6.1M7.1M
Change To Netincome73.2K12.8K(1.1M)301.3K271.2K284.7K

Universe Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Universe Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Universe Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Universe Pharmaceuticals competition to find correlations between indicators driving Universe Pharmaceuticals's intrinsic value. More Info.
Universe Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Universe Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Universe Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Universe Pharmaceuticals Systematic Risk

Universe Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Universe Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Universe Pharmaceuticals correlated with the market. If Beta is less than 0 Universe Pharmaceuticals generally moves in the opposite direction as compared to the market. If Universe Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Universe Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Universe Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Universe Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.

About Universe Pharmaceuticals Financials

What exactly are Universe Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Universe Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Universe Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Universe Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Universe Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Universe Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Today, most investors in Universe Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Universe Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Universe Pharmaceuticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.31

At present, Universe Pharmaceuticals' Price Earnings To Growth Ratio is projected to increase significantly based on the last few years of reporting.

Universe Pharmaceuticals March 24, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Universe Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Universe Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Universe Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Universe Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Universe Pharmaceuticals's daily price indicators and compare them against related drivers.

Complementary Tools for Universe Stock analysis

When running Universe Pharmaceuticals' price analysis, check to measure Universe Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universe Pharmaceuticals is operating at the current time. Most of Universe Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Universe Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universe Pharmaceuticals' price. Additionally, you may evaluate how the addition of Universe Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.